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WNT5A is a secreted ligand involved in differentiation, proliferation, cell 
movement, and apoptosis. Various studies have shown WNT5A misregulation in cancer 
and that it can act as both a tumor suppressor, and oncogene. The WNT5A gene has two 
transcription sites, producing mRNA transcripts that code for unique protein isoforms, 
termed Isoform A and Isoform B in this lab. In a recent study, Isoforms A and B were 
found to differentially effect proliferation, indicating the isoforms are functionally 
distinct.  The focus of this study was on the functional distinctions between the WNT5A 
Isoform A and Isoform B in the osteosarcoma cell line SaOS-2. In osteosarcoma, levels 
of Isoform A expression are higher than normal in normal osteoblast, whereas Isoform B 
expression is nonexistent, indicating it is functioning as a tumor suppressor. Stable lines 
of SaOS-2 were generated expressing Isoform B, overexpressing Isoform A and 
expressing GFP, as a control. The cell lines were confirmed to expresses the expected 
isoform mRNA at higher levels than that of the control and to have correspondingly 
higher levels of WNT5A protein. These cell lines were used in assays for proliferation, 
migration, invasion, and apoptosis. Results show that Isoform A overexpression 
stimulates migration and apoptosis resistance, whereas increased Isoform B had no effect.  
This indicates that Isoform A and Isoform B each stimulate separate non-canonical WNT 
signaling pathways independent from one another. Increased Isoform B expression 
slightly inhibited invasiveness, but the results are still inconclusive. Both Isoform A and 
Isoform B both had no effect on proliferation, relative to the GFP control. Overall, these 
results suggest that Isoform A and Isoform B are functionally distinct, and that the two 
different isoforms activate different non-canonical pathways.
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CHAPTER I 
INTRODUCTION 
WNT5A, a secreted protein of the WNT signaling pathway, is well known for its 
role in the cellular differentiation and organ development, as well as proliferation and 
cellular migration. Studies have shown that it plays a role in many human cancers, acting 
as both a tumor suppressor and oncogene. WNT5A was found to be over expressed in 
osteosarcoma, melanoma, lung, and breast cancers and silenced in colorectal and gastric 
cancers. The WNT5A gene has two main transcription start sites, promoter A and 
promoter B. These promoters give rise to two transcripts that code for distinct protein 
isoforms, identified as Isoform A and Isoform B. These proteins differ at the N-terminus; 
Isoform A has an additional 15 amino acids in comparison to Isoform B. In 
osteosarcoma, Isoform A is overexpressed, whereas Isoform B is not expressed at all. 
Moreover, both Isoform A and Isoform B are expressed in normal osteoblasts. This leads 
to the question of whether Isoform A has a distinct function from that of Isoform B. It is 
possible the distinct functions of the WNT5A isoforms are responsible for the oncogenic 
or tumor suppressor activity of WNT5A in different cancers, including osteosarcoma. 
Many different proteins have isoforms, which show distinct functional differences. 
Considering WNT5A’s importance in cancer and normal cellular functions, it was
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important to analyze and characterize the functional distinctions between WNT5A 
isoforms A and B.  
WNT Proteins and Function 
The WNT proteins are a large family of cysteine-rich proteins, within the size 
ranged of 40 kDa. They are a class of proteins that function as secreted ligands. There are 
a total of 19 WNT ligands, each defined by amino acid sequence rather than their 
functional properties (Clevers & Nusse, 2012). WNTs are important in the orchestration 
of a large range of developmental and physiological processes. These include 
proliferation, differentiation, apoptosis, survival, migration, and polarity (Logan & 
Nusse, 2004). WNTs achieve these functions by activating multiple intracellular 
signaling cascades.  
 As secreted proteins, WNTs must pass through the endoplasmic reticulum (ER)-
Golgi system. WNT proteins undergo palmitoylation of cysteine and serine in the 
endoplasmic reticulum (Li et al., 2010). They are eventually secreted out of the cell 
through the Golgi apparatus. Palmitoylation activates WNTs but also accounts for the 
proteins hydrophobicity and poor solubility. This WNT modification is performed 
primarily by two specific proteins, Porcupine and Wntless (Burrus & McMahon, 1995; 
Tanaka et al., 2002). Porcupine (Porc) (multipass transmembrane O-acyltransferase) 
modifies the serine 209 via palmitoylation.  Wntless (Wls), putative G-protein coupled 
receptor, transports the modified WNT from the Golgi in vesicles to the plasma 
membrane, where it is released.   
3 
 
WNT Signaling 
WNTs function by binding to a cell surface receptor. WNT receptor is a 
heterodimeric receptor complex consisting of two parts, Frizzled and LRP5/6. Frizzled 
(Fz) seven-transmembrane (7TM) receptors have large extracellular N-terminal cysteine-
rich domains (CRD) that provide a primary platform for WNT binding (Bhanot et al., 
1996). A single WNT can bind multiple Fz proteins and vice versa.  LRP5 is essential for 
embryonic development, whereas LRP6 is important for adult bone homeostasis (Clevers 
& Nusse, 2012; MacDonald, et al., 2009). The formation of the WNT/Frizzled/LRP (5/6) 
complex is sufficient to activate β-catenin signaling. However, certain WNTs may 
activate β-catenin pathway (also known as canonical pathway) and/or non-canonical 
pathways depending on the receptor complement (van Amerongen et al., 2008). Fz 
function is involved in both the β-catenin and non-canonical pathways, whereas the 
LRP5/6 is only associated with the β-catenin pathway. 
β-catenin (canonical) Pathway 
The β-catenin pathway has a WNT-on state, and a WNT-off state  (Logan & 
Nusse, 2004; MacDonald et al., 2009).  In the WNT-off state (where no WNT ligand is 
present), cytoplasmic β-catenin is regulated by the APC/Axin Destruction Complex 
(Kimelman & Xu, 2006). Axin, a scaffolding protein, acts as the main component of the 
destruction complex, interacting with β-catenin, the tumor suppressor proteins APC and 
WTX (MacDonald et al., 2009). Also included are CKIα/δ and GSK3a/β, two 
constitutively active serine-threonine kinases. Although the specific molecular activity 
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for APC remains unresolved, it is essential for the destruction complex function. Axin 
uses separate domains to interact with CKIα/δ, GSK3a/β and β-catenin. Due to no WNT 
ligand present Fz/LRP receptors are not engaged, β-catenin is essentially bound to the 
Axin/APC Destruction Complex, and is phosphorylated by CKIα/δ and GSK3a/β. The 
phosphorylated β-catenin is then recognized by the F-box/WD repeat protein β-TrCP, 
part of an E3 ubiquitin ligase complex. This leads to protein degradation of β-catenin by a 
proteasome (Clevers & Nusse, 2012). 
In the WNT-on state (where the WNT ligand is present), the formation of the 
WNT /Frizzled/LRP(5/6) complex results in a ligand-induced conformational change.  
This leads to the LRP tail undergoing phosphorylation by the kinases, CKIα/δ and 
GSK3a/β. The phosphorylation leads to binding of Axin to the cytoplasmic tail of LRP6 
(Mao et al., 2001). Fz receptor interacts with Dishevelled (Dsh/Dvl), a cytoplasmic 
scaffolding protein, which seems critical for LRP phosphorylation. WNT binding of Fz 
and LRP promotes direct interaction between Axin and Dsh/Dvl through their DIX 
domains, reconfiguring the destruction complex that regulates β-catenin levels in the cell 
(Schwarz-Romond, et al., 2005). In short, the APC/Axin Destruction Complex is 
prevented from forming, thus preventing β-catenin degradation. The β-catenin moves into 
the nucleus and interacts with the DNA-binding protein Lymphoid Enhancer-binding 
Factor 1/T Cell-specific transcription Factor (LEF/TCF)(Logan & Nusse, 2004). The β-
catenin- LEF/TCF complex activates WNT target genes. 
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β-catenin independent (non-canonical) Pathways and WNT5A signaling 
There are two types of WNT pathways that do not involve β-catenin. These 
include the PCP/CE (Planar Cell Polarity/Convergent Extension) and the Ca
2+
 signaling 
pathways (Figure 1). Of the several non-canonical WNT pathways, the most extensively 
studied pathway is the PCP/CE  (Wang, 2009). Planar cell polarity is derived from the 
study of tissue polarity necessary to generate polarization within the plane of the 
epithelium. Non-canonical-WNTs, such as WNT5A, activate the PCP/CE pathway by 
binding to the 7-transmembrane Fz receptor, which recruits the cytoplasmic scaffold 
protein Dsh/Dvl to the plasma membrane (Simons & Mlodzik, 2008) (Figure 1). This 
causes a downstream effect in promoting JNK, ROCK, and Rho GTPases (Rho and Rac), 
which eventually promotes cell polarity and migration (Wang, 2009). Due to the PCP/CE 
pathway’s role in cell adhesion and mobility, WNT5A has been implicated in the role of 
WNTs in metastasis (Yamaguchi et al., 2005). In fact, increased WNT5A expression has 
been associated with metastasis of melanoma, gastric cancer, and osteosarcoma cancer 
cells (He et al., 2008; Kurayoshi et al., 2006; Weeraratna et al., 2002).  
The WNT Ca
2+
 signaling pathway is the least studied non- β-catenin pathway. 
The binding of WNT ligand to Fz receptor leads to a short-lived increase in the 
concentration of certain intracellular signaling molecules, specifically inositol 1, 4, 5-tri-
phosphate (IP3), 1, 2 diacylglycerol (DAG). Both can lead to increased Ca
2+
 levels, 
which in turn activate Ca
2+
/Calmodulin-dependent Protein Kinase II (CaMK-II) and 
Protein Kinase C (PKC) (Kohn & Moon, 2005). They, in turn, can activate nuclear 
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transcription factors NF-κB and CREB, which activate gene expression. WNT5A has 
been shown to activate the Ca
2+
 signaling pathway (Figure 1). 
WNT5A can bind to receptor-like tyrosine kinase (Ryk) and Fz receptors family 
members Fz3, Fz4, Fz5, Fz7 and Fz8, mediating phosphorylation of Dvl and influencing 
β-catenin signaling (Kikuchiet al., 2012; Takada et al., 2007).  The PDZ domain of Dvl 
directly binds to the Fz’s C-terminus KTxxxW motif. There may be heterotrimeric G 
proteins that might be coupled with WNT signaling, but at the moment, there is no 
evidence to sustain this (Schulte & Bryja, 2007). WNT5A can also bind to receptor 
tyrosine kinase-like orphan receptor 2 (Ror2) (Nishita, et al., 2010). Ror2 functions as a 
co-receptor, and is more involve in WNT5A signaling. In one study, WNT5A knockout 
mice phenotypes were similar to those lacking Ror2, rather than those lacking Fz (Oishi 
et al., 2003). Ror2 have been shown to form a ternary complex with WNT5A and Fz 
receptors (Fz5, Fz6 or Fz7). It has been also suggested that Ror1 is also a receptor for 
WNT5A (De, 2011). 
Other than the two non-canonical pathways, there are recent findings showing 
other signaling cascades that are activated by WNT5A. These include Dvl activating 
atypical PKC, generating a downstream signaling resulting in axon differentiation. This is 
done probably through the Partitioning Defective Homologue 3 (PAR3)-PAR6- αPKC 
complex(X. Zhang et al., 2007). WNT5A has also been shown to activate 
phosphatidylinositol-3 kinase (PI3K)/ Protein kinase B (AKT) signaling. The activation 
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of PI3K/AKT signaling pathway resulted in a resistance to apoptosis and cell movement 
(Anastas et al., 2014; A. Zhang et al., 2014). 
WNT5A is also shown to interact with the canonical β-catenin pathway as well ( 
Li et al., 2010; McDonald & Silver, 2009). It has been shown that WNT5A affects the β-
catenin pathway either in an agonistic or antagonistic approach (X. He, 1997; Torres et 
al., 1996). The result of this interaction induces changes in cell migration, cell polarity, 
differentiation, as well as proliferation. It is possible that the WNT5A Isoform A and 
Isoform B are differentially affecting the non-canonical pathways. 
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Figure 1. WNT5A Non-canonical Signaling Pathways. A. The planar cell polarity 
(PCP)/convergent extension (CE) pathway. WNT5A signaling cascades through this 
pathway affect cytoskeletal changes, cell migration and cell polarity via Rho and JNK 
kinases. B. The Calcium (Ca2+) pathway. WNT5A signals through this pathway inhibit 
β-catenin and gene expression. This leads to cell migration. CaMK, Ca2+/calmodulin-
dependent kinase; Dvl, disheveled; Fz, Frizzle; PKC, protein kinase C; JNK, c-Jun N-
terminal kinase; Tcf/Lef, T-cell factor/lymphoid enhancer factor. Based on diagrams in 
Kikuchi et al. (2012) and Nishita et al. (2010).  
 
WNT5A: Gene, Protein Structure and Function 
The WNT5A gene is found on Chromosome 3, band p13.3 between 55,499,744 
and 55,521,331 base pairs (Ensembl WNT5A EN5600000114251). In humans, there are 
eight WNT5A transcripts, three of which give rise to complete proteins. Two of these 
transcripts, termed promoter A and promoter B, are being analyzed in this lab. Promoter 
A is the most characterized WNT5A transcript. The promoter B transcriptional start site is 
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located in intron 1 of promoter A transcription unit (Figure 2). The promoter A transcript 
includes exons 1, 2, 3, 4, and 5. The promoter B transcript has a unique exon 1β and 
shares exons 2, 3, and 4 and exon 5 with the promoter A transcript. 
 
 
Figure 2. WNT5A Gene Transcripts. A. Promoter A and Promoter B transcription start 
sites and exons, located on Chromosome 3. B. Promoter A and Promoter B primary 
transcripts. Black boxes are coding regions; open boxes are untranslated regions. Sizes in 
nucleotides of the exons and introns are shown in parenthesis. Exon 1 is unique to 
Promoter A, whereas Exon 1β is unique to Promoter B. This diagram is based on the 
Ensembl EN5600000114251, Bauer et. al, 2013, and Vaidya et al, submitted.  
 
Translation of these two transcript give rise to two protein isoforms, labeled as 
Isoform A (380 amino acids) and Isoform B (365 amino acids). Isoform B differs from 
Isoform A, as it lacks the first 15 amino acids at the N-terminus peptide sequence (Figure 
3). The two isoforms have been recently purified and characterized (Bauer et al., 2013). 
They found that the isoforms have different ER signal sequences and after processing 
differ by 18 amino acids on their N-terminus. The two processed WNT5A isoforms, 
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WNT5A-long (WNT5A-L) and WNT5A-short (WNT5A-S) correspond to the 
preprocessed Isoform A (long) and Isoform B (short). 
As with other WNT proteins, post- translational modification of WNT5A includes 
palmitoylation and glycosylation (Burrus & McMahon, 1995).  The protein is 
glycosylated at specific asparagine-linked sites. The possible sites where glycosylation 
occur are Asn114, Asn120, Asn311, and Asn325. Palmitoylation occurs at Ser-244. This 
modification allows efficient binding to frizzled receptors.  Palmitoylated Ser-244 leads 
to the subsequent palmitoylation at Cys-104. Biochemical analysis of the purified 
WNT5A isoforms indicate that both have the same hydrophobicity (Bauer et al., 2013). 
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Figure 3. Human WNT5A Amino Acid Sequence for Isoform A and Isoform B. The 
15 AA’s unique to Isoform A is highlighted in gray. The unhighlighted amino acids are 
common to both Isoform A and Isoform B 
  
Bauer et al., (2013) determined the role of WNT5A-L (Isoform A) and WNT5A-S 
(Isoform B) on the canonical WNT signaling pathway and on proliferation in various 
cancer cell lines. Using a TOPFLASH- Luciferase assay, they were able to show that 
both isoforms antagonized the β-catenin pathway in MDA-MB-231 (derived from a 
breast carcinoma) and Human Embryonic Kidney 293 cells (HEK293) in a similar 
manner. In MDA-MB-231, HeLa (cervix carcinoma) and SH-SY5Y (neuroblastoma) 
cells, proliferation and viability were shown to be inhibited by WNT5A-L (Isoform A), 
but promoted by WNT5A-S (Isoform B).  However, they did not assay for the effects of 
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the isoforms on cell migration, invasiveness, or differentiation, nor on the activation of 
the non-canonical pathways. 
Studies from this lab also indicate that isoform A and B have distinct functions. It 
was found that promoters A and B are differentially regulated by TNF-α (Katula et al., 
2012) and during differentiation of 3T3L1 cells into adipocytes (Hsu, 2012). Moreover, 
promoter B was found to be silenced in the osteosarcoma cell line SaOS-2, whereas both 
promoters A and B are active in normal osteoblast cells (Vaidya, 2013). These studies 
strongly support the conclusion that WNT5A Isoform A and Isoform B have distinct 
functions. 
WNT5A Cellular Functions 
WNT5A is involved in cell migration, which includes convergent extension 
movement. It has been shown that the receptor Ror2 bound by WNT5A induces cell 
migration in embryonic fibroblast (Nishita et al., 2010). Ror2 mediates the formation of 
filopodia by associating with the actin-binding protein filamin A. In melanoma cells and 
T cells, it also has been proposed that WNT5A controls cell polarity and directional 
migration through the recruitment of Fz3, actin, and myosin IIB with Melanoma Cell 
Adhesion Molecule (MCAM, also known as MUC18 and CD146)  into intracellular 
structure (Witze et. al., 2008). WNT5A has been suggested to cooperate with integrin 
signaling in cell migration/adhesion regulation though Fz receptors. WNT5A stimulation 
forms the Dvl/APC complex, which sequentially bind to FAK (focal adhesion kinase) 
and paxillin, both which are also involved in the stabilization of microtubules at the cell 
13 
 
periphery (Matsumoto et al., 2010).  This induces disassembly of the focal adhesion, 
stimulating cell migration.  
WNT5A is important in development and cellular differentiation, particularly of 
mesenchymal cells. Related to its function in cell movement, WNT5A has a role in 
gastrulation (Hardy et al., 2008), and limb formation (Gros et al., 2010). WNT5A 
knockout mice lack distal digits, as well as having a truncation of the proximal skeleton 
(Oishi et al., 2003). Mesenchymal stem cells can differentiate into adipocytes, 
chondrocytes, and osteoblast. Evidence suggests that WNT5A promotes chondrocyte 
differentiation (Bradley & Drissi, 2010) and suppress formation of adipocytes and 
chondrocyte hypertrophy(Bradley & Drissi, 2010). And, more recently, in one study 
WNT5A-induced non-canonical signaling was shown to cooperate with WNT/β-catenin 
signaling to achieve proper osteoblast differentiation and bone formation (Okamoto et al., 
2014). WNT5A may also have a role in the differentiation of haematopoietic stem cells 
and the function in axonal outgrowth ( Li et al., 2013). 
WNT5A in Cancer 
Most observations of WNT5A in cancer show it as a oncogene, but it has been 
suggested to act as an tumor suppressor as well. WNT5A is highly expressed in several 
cancers, such as osteosarcoma, melanoma, lung cancer, gastric cancer and breast cancer 
(Kurayoshi et al., 2006; Weeraratna et al., 2002). In melanoma, WNT5A induces an 
epithelial mesenchymal transition though protein kinase C (PKC)(Weeraratna et al., 
2002). The involvement of PKC has been linked to increased cell mobility in several 
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types of cells, including melanocytes. In gastric cancer and prostate cancer cases, those 
that were positive for WNT5A showed higher tumor aggressiveness (Kurayoshi et al., 
2006). In fact, WNT5A was used as a prognostic indicator in gastric cancer patients, 
being helpful in determining proper therapeutic strategy.  
In this lab, the WNT5A isoforms have been analyzed in two types of cancers. 
Isoform A and Isoform B transcripts were found to be greatly reduced in the colorectal 
cell line HCT-116, indicating both promoters A and B were silenced (unpublished data). 
In contrast, in the osteosarcoma cell line SaOS-O2, promoter A is active, whereas 
promoter B was entirely inactive (Hsu, 2012). Bauer et al (2013) found that WNT5A-S 
(Isoform B) and WNT5A-L (Isoform A) are expressed in the three cancer cell types they 
examined; MDA-MB-231 (breast carcinoma), HeLa (cervix carcinoma), and SH-SY5Y 
(neuroblasoma), but that only in HeLa was WNT5A-S (Isoform B) expressed at a higher 
level than WNT5A-L (Isoform A). Those findings suggest that WNT5A promoters A and 
B are differently regulated during cellular transformation.  
WNT5A also plays a role in metastasis and invasion. In one study, metastasis was 
severely suppressed when WNT5A was knockdown in gastric cancer cells (Yamamoto et 
al., 2009). WNT5A signaling might be linked to the expression of matrix 
metalloproteases (MMP) genes, a common target gene in cancer invasion (Yamamoto et 
al., 2010). In osteosarcoma, WNT5A activates c-Src, through Ror2. This leads to the 
expression of MMP-13 (Enomoto et al., 2009). Laminin γ2, another gene involved in 
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invasion and metastasis, was also stimulated by WNT5A signaling. The distinct function 
of the WNT5A isoforms in metastasis and invasion is not known.  
Project Overview 
 WNT5A, a non-canonical WNT protein, is important in the regulation of 
differentiation, proliferation, and development in general. It is modified in cancer. 
WNT5A exists as two different isoforms, A and B. The promoters of each appear to be 
regulated differentially. This suggests that the two isoforms A and B are functionally 
distinct. My hypothesis is that WNT5A Isoform A regulates those three traits in a one 
fashion, whereas WNT5A Isoform B regulates the traits in an opposite fashion.Indeed, 
recent published data supports this hypothesis (Bauer et al., 2013). The goal of this 
project was to discover and establish the functional differences between WNT5A 
isoforms A and B, based on assays for proliferation, migration and invasion.  We also 
assayed for effects on chemical induced apoptosis. To accomplish this goal, I completed 
the following specific aims: 
1. Generated and characterized stable lines of human SaOS-2 osteosarcoma cells 
overexpressing WNT5A Isoform A and Isoform B. 
2.  Determined if overexpression of WNT5A Isoform A and Isoform B in SaOS-2 
alters migration, invasion, proliferation, and apoptosis. 
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CHAPTER II 
MATERIALS AND METHODS 
Cell Culture 
Mouse L-Cells (CRL-2648) and SaOS-2 (HTB-85) osteosarcoma cells were 
obtained from the American Type Culture Collection (ATCC). The mouse L-Cells were 
grown in ATCC Hybri-Care Medium (#46-X with 1.5 g/l sodium bicarbonate and 10% 
fetal bovine serum). The SaOS-2 cells were grown in McCoy’s 5a Modified medium 
containing 15% fetal bovine serum and penicillin/streptomycin (50 I.U. /50 µg per ml) 
(referred to as 15% Complete McCoy’s 5a). Both mouse L-Cell and SaOS-2 cells were 
grown at 37°C in a 5% CO2 humidified cell culture incubator. 
DNA Transfection 
SaOS-2 and mouse L-cells were divided in to three groups and plated at 5-10 x 
10
6 
cells per plate in 6 x 60 mm dishes (2 plates per group). Each group was transfected 
with a specific expression vector containing cDNA for the WNT5A isoforms (Figure 4). 
One group was transfected with WNT5A Isoform A expression vector, pWNT5AisoA, 
containing the WNT5A Isoform A cDNA sequence NM_003392, which was purchased 
from Origene (SC126838). The second group was transfected with WNT5A isoform B 
expression vector (Clone ID MESAN2003376) purchased from the National Institute of   
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Technology and Evaluation (NITE; Chiba, Japan). This vector contains the cDNA 
sequence AK290869. The third group was transfected with a vector that expresses Green 
Fluorescent Protein (GFP), pRNATinH1.2/Hygro.  
 
Figure 4. Vectors Used for Transfection 
A. Expression Vector pCMV6-XL4. Isoform A cDNA (NM_003392) cloned into 
Not 1 – Not 1 (OriGene) 
B. Expression Vector pME18SFL3. Isoform B cDNA (AK290869) cloned into the 
Dra III and Dra III (re place stuffer region) (NITE) 
C. Expression Vector pRNATin-H1.2/Hygro, with cGFP (GenScript) 
D. Expression Vector pMC1neopolyA (Invitrogen) 
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Transfection was accomplished using NanoJuice (Novagen 71902-3). Vector 
DNA (pWNT5AIsoA, pWNT5AIsoB, and pGFP) was mixed at a molar ratio of 5:1 with 
the selection vector pMC1neopolyA (pNeo) (Invitrogen). 72 hours after transfection, 
cells were viewed, collected by trypsinization and replated in 100 mm dishes in 10 ml of 
fresh medium. G418, final concentration of 0.44 mg/ml, was added to the medium. 
Selection of cells was continued until cell death stopped or diminished. The resulting 
resistant clones were collected by trypsinization and replated again in medium containing 
G418 (0.44 mg/ml). After further growth, the resistant cells were collected and frozen (-
80°C) in complete medium containing 5% dimethyl sulfoxide (DMSO).  
RNA Isolation/qRT-PCR 
Cells from each stable lines (SaOS-2 Iso A, SaOS-2 Iso B, and SaOS-2 GFP) were 
washed in 5 ml cold 1x phosphate buffered saline (PBS). Another 5 ml 1x PBS were 
added and the cells were removed with scraping. The cells were pelleted by 
centrifugation. RNA was isolated from cell PELLETS using SV Total RNA Isolation 
System (Promega, Z3105). The concentration and purity of the RNA was determined by 
reading the samples at 260 and 280 nm. cDNA samples were generated from 1 μg of 
isolated RNA using QuantiTect Reverse Transcription Kit (Qiagen, 205313). 
Quantitative RT-PCR was conducted using Applied Biosystems Taqman primer-probes. 
Custom primer-probes unique to Promoter A and Promoter B were used to detect 
transcripts derived from each promoter (Katula et al, 2012). A commercial TaqMan 
primer-probe to actin (Applied Biosystems, 4331182) served as an internal control for 
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standardization. Each reaction consisted of 1x TaqMan buffer, cDNA and specific 
primer-probes for a total of 10 μl. Reactions were run in triplicate. Standard instrument 
amplification conditions were used: 95°C for 15 seconds, 65°C for 1 min and 40 cycles. 
Western Blot 
Cell pellets were collected as previously described for RNA isolation. Cells were 
then lysed using Cell Extraction Buffer (Invitrogen, FNN0011) containing Protease 
Inhibitors (Roche, 11777700). Protein concentration was determined using Pierce 660 nm 
Protein Assay Reagent (Thermo #2260). 20-50 μg of proteins was separated on a 10% 
SDS–PAGE gel and transferred to a nitrocellulose filter paper. WNT5A was detected 
using Abcam anti-rabbit WNT5A primary antibody (ab174100, Abcam). The amount of 
primary antibody used was 6 ml of 6µl of primary antibody in 1 % milk. The secondary 
antibody used was a goat anti-rabbit IgG horseradish peroxidase (HRP). The amount of 
secondary antibody used was 6 ml of 1µl of secondary antibody in 1 % milk Detection 
was done with SuperSignal West Pico Chemiluminescent Substrate (Thermo# 34080). 
The bands were visualized on a Bio-Rad Chemi Doc System. The expected molecular 
weight of WNT5A is 41 kDa. 
Cell Proliferation Assay 
  Stable lines of SaOS-2 expressing WNT5A Iso A, Iso B and GFP were plated in 
a 96-well plate at a density of 5 x 10
3
 cells per well. Cells were assayed for proliferation 
using CyQUANT ® NF Cell Proliferation Assay (Invitrogen) over a 4 day period. A 
group of cells were selected on a specific day. The medium was removed from the cells 
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and 50 µl of 1x HBSS/CyQUANT NF Dye reagent mix was added per well. The cells 
were then incubated 30 min at 37°C. DNA florescence was recorded using a BioTeck 
Synergy 2 plate reader, measuring at 485 nm excitation, 530 nm emission for the selected 
wells. Control wells for background contain no cells. The levels of emitted fluorescence 
minus background were recorded for each day. One day after plating the cells was 
considered Day 0.  
Although cells numbers should be equal on Day 0, this was not always the case. 
To standardize the cell lines, the percent change in cell number was plotted by dividing 
each day’s fluorescence values by day 0 for that cell line. The standard error for each 
sample was determined for each day using replica samples. 
Migration Assay 
Cell mobility of stably transfected SaOS-2cells expressing WNT5A Isoform A, 
Isoform B, and GFP was assessed with a scratch/wound assay (O’Connell, 2008). Cells 
(1.4 x 10
6
 /well) were plated into 6-well plate and grown to about 80–90% confluency. 24 
hours later, the confluent cell monolayers were carefully “wounded”. A 200 μl yellow 
plastic pipette, melted in a blue flame, was used to make five scratches vertical in each 
well. Each culture was washed twice with 1x Hank’s balanced salt solution to remove 
cellular debris and fresh medium was then added. The wounded cell monolayers were 
photographed under a phase-contrast light microscope at 0, 24, 45, and 63 hours after. 
The movement of cells into the scratch area was quantified using Image Pro (Media 
Cybernetic) to measure the thickness (width) of the scratches at each time points.  
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The thickness of each scratch were then used to calculate the distance cells 
traveled from the starting point (0%) where the cells were initially after the scratch, to the 
endpoint (100%) where the cells have reach the middle of the scratch. 
Invasion Assay 
Invasiveness stably transfected SaOS-2cells expressing WNT5A Isoform A, 
Isoform B, and GFP were assayed using CytoSelect
TM
 24-Well Cell Migration and 
Invasion Assay (CELL BIOLABS, INC, # 100-C). Cells were suspended to 0.5-1.0 x 10
6
 
cells/ml in serum free media. A cell culture insert, containing a polycarbonate membrane 
(8 µm pore size), was placed into a well on a 24- well plate and warmed to room 
temperature for 10 minutes. The basement membrane of the upper chamber of the insert 
was then rehydrated with serum-free medium. 500 µl of media containing 15% fetal 
bovine serum was added to well itself, rehydrating the outer membrane. 300 µl of the 
sample cell suspension was then placed in the upper chamber, where the cells that are 
invasive can pass through the basement membrane. After a 12- 48 hour incubation, the 
non-invasive cells in the top chamber were then removed with a Q-tip, whereas the 
invasive cells that have passed through the membrane are stained with Cell Staining 
Solution. After staining, the cells were washed with dd H2O and extracted using Cell 
Extraction Solution. 100 µL of each sample was transferred to a 96-well microtiter plate 
and the absorbance read at OD 560 nm measured using a BioTeck Synergy 2 plate reader.  
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Apoptosis Assay (Cell Viability Assay) 
Stable lines of transfected SaOS-2cells expressing WNT5A Isoform A, Isoform 
B, and GFP were assayed for apoptosis using a doxorubicin (DOX)-induced apoptosis 
assay (Tsang, 2005). The cells were plated at a density of 3.5 x 10
4
 into a 24-well plate. 
Each cell line was then divided into 3 groups based on the amount of DOX that was to be 
administered to each group (0 µM, 0.1µM, and 0.2 µM). The next day, the appropriate 
amount of DOX was administered to each group per well. After 3 days, the cells were 
then collected and counted for survivability. The percent of cells that survived was 
calculated based on the control, untreated as 100%. 
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CHAPTER III 
RESULTS 
Establishment of Stable Lines 
As one approach to determine the functions of the WNT5A Isoforms A and 
Isoform B, stable lines of SaOS-2 overexpressing A and B were generated. SaOS-2 cells 
essentially do not express Isoform B, but express Isoform A at a slightly higher level than 
normal osteoblasts (unpublished, this lab). Expression vectors for each isoform were 
obtained (see Figure 4) and transfected into SaOS-2, along with the selection vector, 
pMC1neopolyA. A control cell line was also made, transfected with a GFP expression 
vector pRNATinH1.2/Hygro. Cells were selected in G418, as described in Materials and 
Methods, and collected as a heterogeneous group. 
The stable SaOS-2 cell lines were characterized to confirm that the expected 
isoform RNA was being made and that the level of WNT5A protein was increased. RNA 
was isolated from the three stable cell lines, SaOS-2 Iso A, SaOS-2 Iso B, and SaOS-2 
GFP and analyzed by qPCR using custom Taqman primer-probes (Figure 5A). Results 
show that in SaOS-2 Iso B, Isoform B mRNA expression was extremely high, in 
comparison to control cells that showed little or no expression of Isoform B. The level of 
Isoform A mRNA in SaOS-2 Iso B cells was nearly the same as in the control SaOS-2 
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GFP cell line, as expected. Isoform A expression in SaOS-2 Iso A cells was also high, in 
comparison to control cells, which express some Isoform A. 
Protein lysates were prepared from the three stable lines, SaOS-2 Iso A, SaOS-2 
Iso B, and SaOS-2 GFP, and analyzed by western blot. The antibody used will detect 
both isoforms, so it was not possible to determine if only the A or B isoform was being 
made. However, when compared to the GFP control cells, the amounts of WNT5A 
protein increased, with SaOS-2 Iso B having the highest amount (Figure 5B). WNT5A 
protein also increased in the SaOS-2 Iso A cells, but not to the same level as Iso B cells. 
This correlates with the detected RNA levels (Figure 5A). 
 
 
Figure 5. Expression of WNT5A mRNA and Protein in SaOS-2 Stable Lines. A. 
WNT5A Isoform A and Isoform B transcript levels were quantified in the SaOS-2 Iso A, 
SaOS-2 Iso B, and SaOS-2 GFP cell lines by qPCR. Transcript levels were normalized 
relative to actin levels transcript. B. WNT5A protein in the same cell lines were 
characterized by immunoblot. 100 µg of total cell lysate was loaded per lane. The arrow 
indicates the position of the WNT5A protein at approximately 41 kDa. An unknown non-
specific band is always detected at 72 kDa. The L-cell WNT5A is a purchased mouse cell 
line, expressing the WNT5A Isoform A, as a positive control. 
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No Distinction between the Two Isoform A and Isoform B in Proliferation  
There is evidence that WNT5A Isoform A inhibits proliferation, whereas Isoform 
B increases proliferation (Bauer et al., 2013). We wanted to know if over expression of 
Isoform A and Isoform B had the same effect in SaOS-2 cells. This might not be the case, 
since the expression of Isoform B is decreased in SaOS-2. This suggests that Isoform B 
acts as a tumor suppressor. In the cancer types Bauer et al. used in their study, Isoform B 
was expressed and in one cancer cell line, at higher levels than Isoform A. 
In this experiment, each cell line (Iso A, Iso B, and GFP) were plated at an equal 
number in a 96 well plate. The next day (Day1), the cell number was quantified by 
measuring DNA content with a fluorescent DNA binding dye. Then DNA content was 
quantified for the next three days (2, 3, and 4). Result showed there was no distinction in 
cell proliferation between three SaOS-2 cell lines (Figure 6). These data contradicts that 
Bauer et al (2013). The assay was performed multiple times. Although there were some 
variations, from assay to assay, for example, the reduction at Day 3 for GFP and Isoform 
A was inconsistent; the results indicated no efforts of increased Isoform A or B on SaOS-
2 proliferation.  
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Figure 6. WNT5A Isoforms Effects on Cell Proliferation. The cell lines SaOS-2 Iso A, 
SaOS-2 Iso B, and SaOS-2 GFP were assayed for increase in DNA content, as a measure 
of cell number over a three day period. Change in DNA content was expressed as a 
percent of increase from Day 1. Error bars represent standard error with n=5. 
 
Isoform A Promotes Greater Cell Migration 
We then decided to test the effect of increased Isoform A and Isoform B 
expression on cell migration. Our hypothesis was that SaOS-2 cells expressing increased 
Isoform B will migrate and travel at a slower rate than the SaOS-2 cells not expressing 
isoform B. This is based on the fact that Isoform B is not expressed in SaOS-2 cells. Our 
stable lines, SaOS-2 Iso A, SaOS-2 Iso B, and SaOS-2 GFP, were assayed for migration 
using the scratch-wound assay over a 63 hour period. Each scratch was photographed at 
four time intervals, 0, 24, 45, and 63 hours post scratch (Figure 7A). Our results show 
that SaOS-2 cells expressing more Isoform A traveled a greater distance per unit time, in 
comparison to cells expressing Isoform B and the control cells with less Isoform A over 
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three time intervals (Figure 7B). This assay was repeated once with similar results. This 
correlates with both SaOS-2 Iso B cells and the control SaOS-2 cells having roughly the 
same levels of Isoform A transcripts. These data indicate that Isoform B does not play a 
role in cell migration, but that Isoform A enhances migration as previously shown 
(Enomoto et al., 2009). 
 
 
Figure 7. Effects of Increased WNT5A Isoforms A and B Expression on Cell 
Migration  
A. Vertical scratches were created (0 hours) and photographed under phase-contrast 
microscopy. The added lines outline the edges of the scratch or migrating cells. B. The 
distance the cells traveled from the starting point (edge of the scratch at time 0 hrs) to the 
midpoint at each time point was measured. The percent distance traveled was graphed. 
Error bars represent standard error with n=10. * p<0.005 comparing Iso A to GFP. 
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 Increased Isoform B Expression Decreases Cell Invasion 
Next, we assayed the expressing SaOS-2 cells to determine the effect of increased 
Isoform A and B had on cell invasiveness. Our hypothesis was that SaOS-2, cells 
expressing Isoform B would be less invasive than the SaOS-2 cells, expressing little or no 
Isoform B. The transfected cells were assayed using a commercial cell invasion assay. 
The assay uses inserts, each with a coated basement membrane, where only invasive cells 
can pass through. 
For this experiment, the cells were hypothetically plated at an equal number in 
each insert, where the invasive cells would pass though the basement membrane over a 
48 hour period. Unfortunately, it proved difficult to plate the cell lines at equal numbers, 
resulting in one cell line having more cells than the others. Moreover, it was not possible 
to quantify cell numbers after plating into the inserts. Our approach was to plate a 
presumed equal amount of cells, using the same cell stocks as for the invasion assay, in 
96-well plates at the same time the cells are plated for the invasion assay. The next day, 
the DNA content of the cells in the 96-well plates were quantified. This value was used to 
normalize the results of the invasion assay. After the 48 hours, the cells that had invaded 
the insert membrane were stained, extracted and the extracts read at OD560 nm. These 
values were normalized for “cell number plated” based on DNA content, as just 
described. The OD560 /unit DNA serves to quantify the number of invasive cells. 
The results suggest that SaOS-2 cells expressing more Isoform B were less 
invasive, in comparison, to those expressing little to no Isoform B, although significance 
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could not be determined (Figure 8). SaOS-2 Iso B cells had 1.45x less the amount of cells 
invading the insert compare to that of the control cells. There was also a slight difference 
between SaOS-2 Iso A and GFP cells, with SaOS-2 Iso A cells having 1.19x less invasive 
cells than SaOS-2 GFP cells. This assay will obviously have to be repeated in order to 
confirm these results. Our current data supports our hypothesis that cells expressing 
Isoform B would be less invasive than the cells expressing little to no Isoform B. 
 
 
Figure 8. Effects of Increased WNT5A Isoforms Expression on Cell Invasiveness. 
The cell lines SaOS-2 Iso A, SaOS-2 Iso B, and SaOS-2 GFP were used in a cell invasion 
assay. Invasive cells were stained, extracted, and the extracts read at OD560. Values were 
standardized to cell number plated based on DNA content as described. Average of two 
determinates are shown. 
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Increase of Isoform A Provides some Resistance against Drug-Induced Apoptosis 
Transfected SaOS-2 cells expressing increased Isoform A and Isoform B were 
assayed for cell viability undergoing apoptosis induced by a pharmaceutical drug known 
as doxorubicin (DOX). Our hypothesis was that SaOS-2 cells expressing increased 
Isoform B would be more susceptible to apoptosis, and would have fewer living cells 
than SaOS-2 cells expressing little to no Isoform B when induced by DOX.  
Our stable lines (SaOS-2 Iso A, SaOS-2 Iso B, and SaOS-2 GFP) were plated and 
divided into three groups between each cell line. Each group was treated with a specific 
concentration of DOX, 0 µM, 0.1µM, and 0.2 µM, based on a previous study (Tsang et 
al., 2005). After three days, the number of cells in each group was counted, as a measure 
of survivability. Our results showed that SaOS-2 cells with increase Isoform A 
expression are more resistant to DOX-induced cell death (Figure 9). SaOS-2 Iso B cells 
had a similar survivability percentage to that of SaOS-2 GFP cells (8.4% vs 8.9%, 
respectively). These data indicate that Isoform B does not influence cell death, but that 
increased Isoform A makes cells more resistance to apoptosis. Further assays will be 
performed to determine if increased Isoform A alters the the signaling pathway for 
apoptosis, such as caspase activity or annexin A5 affinity. 
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Figure 9. Effects of Increased WNT5A Isoform A and B Expression on Cell 
Survivability after Treatment with Doxorubicin. The cell lines SaOS-2 Iso A, SaOS-2 
Iso B, and SaOS-2 GFP were treated for three days with doxorubicin to induce apoptosis. 
The percent of surviving cells relative to the untreated cells was determined. Cell 
Survivability serves to quantify the number of cells that did not undergo apoptosis. Error 
bars represent standard error with n=4. * p<0.005, ** p<0.01 comparing Iso A to GFP.  
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CHAPTER IV 
 
DISCUSSION 
Summary of Major Findings 
In this study, the functional distinction between the WNT5A isoforms A and B 
were analyzed. Stable lines of SaOS-2 cells were generated to have an increased WNT5A 
protein Isoform A and Isoform B expression. The cells were characterized through qPCR 
and immunoblott to confirm that Isoform A and Isoform B mRNA and protein expression 
were higher than the control cells, transfected with GFP expression vector. These cells 
were assayed to observe the protein isoforms effects on cell proliferation, migration, 
invasion, and apoptosis. Our results showed that Isoform B in SaOS-2 has no effect on 
proliferation, migration, and apoptosis, with a slight inhibitory effect on invasiveness. An 
increase of Isoform A expression simulated migration, whereas an increase of Isoform B 
expression had no effect on migration. Similarly, an increase in Isoform A expression 
made cells more resistance to cell death due to drug treatment, whereas increased Isoform 
B expression had no effect. Increased Isoform B and Isoform A expression had a small 
effect on invasion, although more assays will need to be conducted to verify these 
findings. These results suggest that the WNT5A protein isoforms distinctively stimulate 
the non-canonical WNT pathways. 
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Proliferation in SaOS-2 cells is not affected by either WNT5A Isoform Protein 
A previous study showed that WNT5A isoforms A and B had different effects on 
proliferation (Bauer et al., 2013). The effects of the WNT5A-L (Isoform A) and 
WNT5A-S (Isoform B) were analyzed in three cancer cell lines, MDA-MB-231 (breast 
carcinoma), HeLa (cervical carcinoma), and SH-SY5Y (neuroblasoma). All three cell 
lines expressed both isoforms, but only in HeLa is WNT5A-S (Isoform B) expressed at a 
higher level than WNT5A-L (Isoform A). In the experiment, each cell line was 
transfected with an expression vector containing cDNA for one of the isoforms and 
selected for six days. The cells were then plated and counted at three time intervals over a 
six day period. The results showed that increased WNT5A-S (Isoform B) expression in 
each cell line stimulates proliferation, whereas increase WNT5A-L (Isoform A) 
expression suppresses proliferation. This contradicts our data, where increased Isoform A 
or Isoform B expression showed no distinction from the control cell line, SaOS-2 GFP 
(Figure 6). This indicates that the pathway controlling proliferation is independent from 
the WNT5A non-canonical pathways in SaOS-2. It was expected that Isoform B would 
have acted in an inhibitory fashion in SaOS-2 cells, as the gene promoter for Isoform B is 
inactivated and little or no Isoform B is expressed. It is also possible that the WNT5A 
Isoform B doesn’t have an effect on SaOS-2 cells due to the lack of a receptor for 
Isoform B in SaOS-2 cells. We also expected that Isoform A would stimulate 
proliferation, as it is active in SaOS-2 cells. In comparing our results to Bauer et al 
(2013), they support the general notion that WNT5A has distinct activities in different 
cell cancer types. 
34 
 
Stimulation of Migration by Increased WNT5A Isoform A  
The overexpression of WNT5A Isoform A was shown to stimulate migration in 
SaOS-2 cells. The overexpression of Isoform B, however had no effect on migration 
compared to the control. This suggests that Isoform B does not play a role in cell 
migration. These results differ from that of our expectations of Isoform B, where Isoform 
B would inhibit migration, in comparison to the control. WNT5A Isoform A is known to 
function in cell migration. Considering the opposite effects Bauer et al (2013) observed 
on proliferation for the isoforms and the lack of Isoforms B expression in SaOS-2 cells, it 
seemed a reasonable hypothesis that isoform B would have a negative effect on 
migration. 
Our results for Isoform A are consistent with other published results.  In one 
study, the role of WNT5A/Ror2 signaling on cell migration was investigated (Nishita et 
al., 2010). They used various cell types to show that the Receptor Tyrosine Kinase (RTK) 
Ror2 is essential for WNT5A induction of migration and that Ror2 is mediating actin 
reorganization. This would support the idea that Isoform A is binding to Ror2 in 
osteosarcoma. Another studied looked at WNT5A role in PI3 Kinase/AKT signaling (A. 
Zhang et al., 2014). In that study, Isoform A was shown to stimulate migration by 
enhancing phosphorylation of phosphatidylinositol-3 kinase (PI3K)/AKT. They treated 
osteosarcoma MG-63 cells with different doses (0, 50, 100, and 200 ng/ml) of 
recombinant Wnt5a (rWnt5a), and assay for the migration rate via wound healing assays 
and Boyden chamber assays. Results from the assays showed that WNT5A stimulation 
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increases migration.  They then ran an immunoblot for PI3K and AKT phosphorylation 
on MG-63 cells that were treated with 100 ng/ml of WNT5A.They showed activation of 
both PI3K and AKT at 15 min post treatment. Since only Isoform A and not Isoform B 
affected cell migration in our assay, we conclude, based on the Zhang et al (2014) 
findings, that Isoform A is stimulating a non-canonical pathway leading to PI3K and 
AKT phosphorylation and that Isoform B is not activating this same pathway. Either, as 
previously mentioned, there are no receptors for Isoform B to mediate PI3K and AKT 
phosphorylation or instead Isoform B activates a non-canonical pathway not linked to cell 
migration. 
The Role of WNT5A Isoforms in Cell Invasiveness is still Inconclusive 
A previous study showed that WNT5A/Ror2 signaling plays a role in the 
regulation of cell invasiveness in SaOS-2 cells and U2OS cells, another osteosarcoma 
cell line (Enomoto et al., 2009). They transfected both SaOS-2 and U2OS cells with 
siRNA (control siRNA, Ror2 siRNA, or WNT5A siRNA) and assayed them for cell 
invasiveness using a matrigel consisting of extracellular matrixes (ECM). The invasive 
cells were stained and counted. Results showed that cells transfected with either Ror2 
siRNA, or WNT5A siRNA were less invasive. They also ran an immunoblot for matrix 
metalloproteinase 13 (MMP-13), a protein upregulated in metastatic cells. They found 
that MMP-13 levels were decreased in the absence of WNT5A/Ror2 signaling. Overall, 
the study showed SaOS-2 and U2OS cells displayed invasive like behavior by activating 
WNT5A/Ror2 signaling. This further supports the notion that Isoform A is affecting a 
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non-canonical pathway involving the Ror2 receptor. However, our results indicate that 
Isoform B may have a role on invasiveness. SaOS-2 cells that overexpressed Isoform B 
were the least invasive, compared to that of SaOS-2 cells that overexpressed Isoform A 
and the control GFP.  Also, compared to the control, cells that overexpressed Isoform A 
were somewhat less invasive, which is contrary to the result of Enomoto et al (2009). 
However, it was not possible to determine the significance of these results as only 
a limited number of trials were conducted. This assay would need to be repeated to 
statistically confirm the role of WNT5A isoforms on invasiveness. Also, the assay was 
difficult to perform due to problems with plating the cells at the same cell number. As 
described, we standardized cell number based on DNA content using cells plated in 
separate wells. An alternative approach would be to use condition medium expressing the 
WNT5A isoforms to treat the SaOS-2 cells. However, this approach has its own 
problems, particularly in standardizing the amount of active isoform protein in the 
conditioned medium. Also, it should be mentioned that the cell assay plates are expensive 
(12 inserts costing approximately $400), limiting the number of replicas. 
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Role of WNT5A in Apoptosis Resistance 
A recent study looked into how WNT5A plays a role in melanoma cells resisting 
a therapeutic drug known as BRAF inhibitors (BRAFis) (Anastas et al., 2014). They 
transfected 2 BRAFis resistant melanoma cell lines (A375 and MEL624), with siRNA to 
silence either WNT5A or BRAF expression. Results showed that cells transfected 
WNT5A siRNA showed little resistance to cell death when treated with BRAFis. This 
result suggest that WNT5A has a role in resistance to appoptosis. We based our 
experiment on another study showing that SaOS-2 cells were susceptible to apoptosis in 
the presence of doxorubicin (Tsang et al., 2005). In that study, SaOS-2 cells were treated 
with different concentrations of doxorubicin. They determined that 0.1 µM of 
doxorubicin induced DNA degradation after 72 hours of treatment. We based our assay 
on these findings. As cancer cells are known to avoid apoptosis, we decided to assay for 
cell survivability, as cell death is an endpoint for apoptosis. This was a cost cutting move, 
compared to the use of other assays measuring apoptosis. Initially, we wanted to 
determine if there was any reason to extend our analysis of apoptosis to these more 
precise assays. Our results showed increased Isoform A expression lead to a higher cell 
survivability percentage, in comparison to that of increased Isoform B expression and the 
control. This is not an unexpected result as increased WNT5A would be expected to 
increase survivability. Isoform B showed little to no effect on cell survivability. This is an 
unexpected result. If Isoform B is functioning as a tumor suppressor, then the expressing 
protein should sensitize the cells to apoptosis, resulting in a decrease in survivability, 
relative to the control. 
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Conclusion and Future Studies 
Our results suggest the WNT5A isoforms A and B are functionally distinct. We 
provided evidence that Isoform B decreases invasion, whereas it had no effect on 
proliferation, migration, or apoptosis in SaOS-2. In contrast, Isoform A, as previously 
stated, appears to increase migration and survivability to drug induced apoptosis. The 
differences in response are likely due to stimulation of different non-canonical signaling 
pathways. To confirm these results, it will be necessary to repeat the invasion assay.  
To further our study of the functional distinctions of the WNT5A protein isoforms 
on cell migration, invasion, and apoptosis, we would like to use HCT-116, a colorectal 
cancer cell line, as a new template to assay for these characteristics. Both Isoform A and 
Isoform B are not expressed in HCT-116. In fact, two attempts to generate these lines 
were unsuccessful for different reasons. This makes it a better candidate than SaOS-2, 
where Isoform A is expressed, but Isoform B is not. The further analysis of SaOS-2 cells 
on apoptosis and invasiveness will be conducted as well. Another approach to 
understanding the functional distinction between the two isoforms would be the use of 
condition medium on SaOS-2 cells. As WNT5A is a secreted protein ligand, the cells 
would be treated with condition medium enriched with one of the WNT5A isoforms. Our 
data suggest that Isoform B is signaling through a non-canonical pathway that is different 
from Isoform A. An approach to investigate this question would be to analyze each of the 
downstream signaling proteins of PCP/CE and Ca
2+
pathways in SaOS-2 cells stimulated 
by either WNT5A Isoform A or Isoform B, such as MMP-13. It could also be possible 
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that Isoform B plays a role in cell development and differentiation. If this is so, a 
different experiment system would be required, such as mouse embryos. 
Also the role of WNT5A Isoform A and Isoform B in the stimulation of the 
PI3K/AKT signaling pathway is also another pathway to be studied, as both migration 
and apoptosis resistance are influenced by it. In the study done by Anastas et al (2014), 
PI3K and AKT protein levels were used as a marker, when assaying melanoma cells for 
apoptosis resistance.  Zhang et al (2014) also used PI3K and AKT as markers when 
studying WNT5A’s role on migration This could indicate that WNT5A Isoform A binds 
to Ror2, initiating PI3K/AKT signaling, leading to migration and apoptosis resistance 
(Figure 10). 
We have assayed the role of WNT5A protein Isoforms on apoptosis, but we 
mainly focused on the endpoint. In future studies, we would like to look at other aspects 
along the apoptotic pathway to have a further understanding on how the WNT5A 
Isoforms affect earlier apoptotic markers. Based on what is known about Isoform A, it 
will be important to analyze the levels of activated AKT and phosphorylated Bad in 
SaOS-2 cells. Also, annexin A5 affinity assay could be used to confirm that the cells are 
actually undergoing apoptosis. These methods could give us a better understanding on 
how WNT5A is affecting apoptosis. 
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Figure 10. Model for PI3K/AKT Stimulated by WNT5A Isoform A/Ror2.  
Both apoptosis and cell migration are influence by PI3K/AKT signaling due to WNT5A 
Isoform A. PI3K/AKT signaling leads to the phosphorylation of Bad, a member of the 
Bcl-2 family, rendering it inactive and preventing apoptosis. The axonal skeleton is 
influenced by PI3K/AKT signaling, thus influencing cell movement. 
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